Resource Summary Report

Generated by <u>dkNET</u> on May 1, 2025

Oncomine Research Platform

RRID:SCR_007834 Type: Tool

Proper Citation

Oncomine Research Platform (RRID:SCR_007834)

Resource Information

URL: http://www.oncomine.org

Proper Citation: Oncomine Research Platform (RRID:SCR_007834)

Description: Oncomine Research Platform is a partially-commercial suite of products for online cancer gene expression analysis dedicated to the academic and non-profit research community. Oncomine combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data-mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation and prioritization. Oncomine was developed by physicians, scientists, and software engineers at the University of Michigan and is now fully supported for the academic and non-profit research community by Compendia Bioscience.

Synonyms: OncoMine

Resource Type: analysis service resource, data analysis service, production service resource, service resource

Keywords: FASEB list

Funding:

Resource Name: Oncomine Research Platform

Resource ID: SCR_007834

Alternate IDs: nif-0000-03218, OMICS_00775, SCR_010949

Record Creation Time: 20220129T080244+0000

Ratings and Alerts

No rating or validation information has been found for Oncomine Research Platform.

No alerts have been found for Oncomine Research Platform.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 3608 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>dkNET</u>.

Liu YC, et al. (2025) Targeting the ERK1/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer. Cell communication and signaling : CCS, 23(1), 22.

Liu M, et al. (2025) Identification of Immune Infiltration-Associated CC Motif Chemokine Ligands as Biomarkers and Targets for Colorectal Cancer Prevention and Immunotherapy. International journal of molecular sciences, 26(2).

Ong JLK, et al. (2024) Exosomal mRNA Cargo are biomarkers of tumor and immune cell populations in pediatric osteosarcoma. Translational oncology, 46, 102008.

Benn KW, et al. (2024) hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560. PloS one, 19(9), e0309438.

Huang J, et al. (2024) The Expression Profiles and Clinical Significance of Mixed Lineage Kinases in Glioma. Mediators of inflammation, 2024, 5521016.

Luo Z, et al. (2024) GGT5 facilitates migration and invasion through the induction of epithelial-mesenchymal transformation in gastric cancer. BMC medical genomics, 17(1), 82.

Lee KT, et al. (2024) Benign polymorphisms in the BRCA genes with linkage disequilibrium is associated with cancer characteristics. Cancer science, 115(12), 3973.

Nakano T, et al. (2024) Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer. Cancer science, 115(6), 1989.

Choi HY, et al. (2024) NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram

tumor-initiating cells. Experimental & molecular medicine, 56(2), 461.

Chen B, et al. (2024) A pan-cancer analysis uncovering the function of CRHBP in tumor immunity, prognosis and drug response: especially its function in LIHC. Scientific reports, 14(1), 3112.

Yang YP, et al. (2024) Comprehensive transcriptome and scRNA-seq analyses uncover the expression and underlying mechanism of SYNJ2 in papillary thyroid carcinoma. IET systems biology, 18(5), 183.

Payungwong T, et al. (2024) Comparison of mutation landscapes of pretreatment versus recurrent squamous cell carcinoma of the oral cavity: The possible mechanism of resistance to standard treatment. Cancer reports (Hoboken, N.J.), 7(3), e2004.

Kodama H, et al. (2024) Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer. Thoracic cancer, 15(21), 1665.

Guo M, et al. (2024) Genetic variants in hypoxia-inducible factor pathway are associated with colorectal cancer risk and immune infiltration. Journal of cellular and molecular medicine, 28(1), e18019.

Zhao Z, et al. (2024) Expression and Prognostic Role of PANK1 in Glioma. Combinatorial chemistry & high throughput screening, 27(5), 715.

Li DM, et al. (2024) Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 26(6), 1519.

Xu X, et al. (2024) NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer. Communications biology, 7(1), 206.

Feng Z, et al. (2024) The potential contribution of aberrant cathepsin K expression to gastric cancer pathogenesis. Discover oncology, 15(1), 218.

Feng Y, et al. (2024) Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib. Cell death & disease, 15(8), 588.

Wang DD, et al. (2024) Systematic characterization of the expression, prognosis and immune characteristics of PLOD family genes in breast cancer. Aging, 16(14), 11434.